Rabin Medical Center Conducts Clinical Trial Investigating Steroid-CBD Treatment on Hospitalized COVID-19 Patients

Rabin Medical Center Conducts Clinical Trial Investigating Steroid-CBD Treatment on Hospitalized COVID-19 Patients

Rabin Medical Center’s Golda Hasharon Campus in Petah Tikva commences a small-scale clinical trial to investigate the effects of a steroid-Cannabidiol (CBD) treatment on hospitalized patients infected with SARS-CoV-2. Sponsored by the drug’s maker, Stero Biotechs, the study seeks to capitalize on CBD’s potential ability to enhance the therapeutic effect of steroid treatment while addressing the biomechanism affected by SARS-CoV-2, the virus behind the COVID-19 pandemic.  Stero Biotechs conducts this study in collaboration with Mor Research Applications, the Tech Transfer Office (TTO) of Clalit, the largest Health Maintenance Organization (HMO) in Israel.

The IP

Stero has wide patent coverage for over 130 autoimmune and inflammatory diseases by name, CBD from any source (synthetic or botanic), CBD in combination, CBD in any dosage and in any delivery system. 

The Premise

The goal here is to enhance the therapeutic effect for Steroid treated patients with CBD. Steroid treatment is usually the first or second line of treatment for hospitalized patients. CBD enhances the therapeutic effect of steroid treatment and treats the bio-mechanism affected by the virus.   

David Bassa, Founder & CEO of Stero Biotechs, said: “We estimate that our CBD-based treatment can enhance the current treatment of those patients who are in life-threatening conditions. Hospitalized COVID-19 patients are mostly being treated with steroids and our study is planned to demonstrate the benefit of a combined solution with Steroid treatments. We are hopeful that this study will lead to faster benefit for the growing number of COVID-19 patients in Israel and around the world.”

The Study

Starting immediately, the small-scale clinical trial will treat 10 patients as a proof-of-concept (POC). This initial study seeks to evaluate the tolerability, safety and efficacy of the CBD treatment for hospitalized patients with COVID-19. Patients will be treated every few weeks. Assuming the study goes well, the company seeks to scale up and expand to a Phase 2a multi-center clinical trial, with an additional 40 hospitalized patients with COVID-19 infections, under FDA clinical trial guidelines and regulations.  

The Sponsor

Founded in 2017, Stero Biotechs Ltd. is an Israeli-based, clinical-stage company committed to the research and development of novel Cannabidiol (CBD) based treatment solutions that will potentially benefit millions of patients. According to their press release, their solution enhances the therapeutic effect of steroid treatments, allowing treatments to act more effectively. Simultaneously, the company posits, the solution reduces dosage and side effects and the need for steroid therapy. The company was granted a U.S. patent over 130 potential indications and is planning to commence more clinical trials on various indications.

The Research Site

Rabin Medical Center’s Golda Hasharon Campus in Petah Tikva is a major hospital and medical center located in Petah Tikva, Israel. It is now owned and operated by Clalit Health Services, Israel’s largest health maintenance organization. The hospital was the result of the merger of Beilinson Hospital and Hasharon Hospital in 1996—the new merged entity has a capacity of 1,300 beds.